

## Table of Contents

	Page Number
<b>List of Tables .....</b>	<b>vi</b>
<b>List of Abbreviations and Acronyms.....</b>	<b>vii</b>
<b>Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives .....</b>	<b>x</b>
<b>Acknowledgements.....</b>	<b>xi</b>
<b>Preface .....</b>	<b>xiii</b>
<b>Executive Summary .....</b>	<b>xvii</b>
<b>1.0      Introduction and Rationale for the Proposed Use of <i>In Vitro</i> Pyrogen Test Methods .....</b>	<b>1-1</b>
1.1     Introduction .....	1-1
1.1.1   Historical Background of <i>In Vitro</i> Pyrogen Test Methods and the Rationale for Their Development.....	1-1
1.1.2   Peer Reviews of <i>In Vitro</i> Pyrogen Test Method Validation Studies .....	1-3
1.2     Regulatory Rationale and Applicability .....	1-3
1.2.1   Current Regulatory Testing Requirements and ICCVAM Prioritization Criteria.....	1-3
1.2.2   Intended Uses of the Proposed <i>In Vitro</i> Pyrogen Test Methods .....	1-7
1.2.3   Similarities and Differences in the Endpoints Measured by the Proposed Test Methods and the <i>In Vivo</i> Reference Test Method .....	1-7
1.2.4   Use of the Proposed Test Methods in an Overall Strategy of Hazard or Safety Assessment.....	1-7
1.3     Scientific Basis for the <i>In Vitro</i> Pyrogen Test Methods.....	1-8
1.3.1   Purpose and Mechanistic Basis of the <i>In Vitro</i> Pyrogen Test Methods .....	1-8
1.3.2   Similarities and Differences of Modes of Action Between the <i>In Vitro</i> Pyrogen Test Methods and the Fever Response in Humans and/or Rabbits.....	1-8
1.3.3   Range of Substances Amenable to the <i>In Vitro</i> Pyrogen Test Methods and Limits of These Methods .....	1-9
1.4     Validation of the <i>In Vitro</i> Pyrogen Test Methods.....	1-9
1.5     Search Strategies and Selection of Citations for the ICCVAM BRD .....	1-10
<b>2.0      <i>In Vitro</i> Pyrogen Test Method Protocol Components .....</b>	<b>2-1</b>
2.1     Overview of How the <i>In Vitro</i> Pyrogen Test Methods Are Conducted .....	2-1
2.2     Description and Rationale for the Test Method Components for Proposed Standardized Protocols.....	2-1
2.2.1   Methods Used to Analyze the Data, Including Methods to Analyze for Interference with the Assay .....	2-7
2.2.2   Decision Criteria and the Basis for the Prediction Model Used to Identify a Pyrogenic Substance .....	2-7

2.2.3	Information and Data to be Included in the Study Report and Availability of Standard Forms for Data Collection and Submission .....	2-8
2.3	Basis for Selection of the Test Method Systems .....	2-9
2.4	Proprietary Components.....	2-10
2.5	Number of Replicates .....	2-11
2.5.1	Number of Donors.....	2-11
2.5.2	Number of Assay Replicates.....	2-11
2.6	Modifications to the Test Method Protocols Based on ECVAM Validation Study Results.....	2-11
2.7	Differences Between Comparable Validated Test Methods with Established Performance Standards.....	2-11
<b>3.0</b>	<b>Substances Used for the Validation of <i>In Vitro</i> Pyrogen Test Methods .....</b>	<b>3-1</b>
3.1	Rationale for the Substances or Products Selected for Testing.....	3-1
3.2	Number of Substances .....	3-1
3.3	Identification and Description of Substances Tested.....	3-1
3.4	Sample Coding Procedure.....	3-2
3.5	Rationale for the Selection of the Recommended Reference Substances .....	3-3
<b>4.0</b>	<b><i>In Vivo</i> Reference Data for the Assessment of Test Method Accuracy .....</b>	<b>4-1</b>
4.1	Description of the Protocol Used to Generate <i>In Vivo</i> Data .....	4-1
4.1.1	The Rabbit Pyrogen Test (RPT).....	4-1
4.1.2	Current <i>In Vivo</i> Pyrogen Test Method Protocols .....	4-5
4.2	Reference Data Used to Assess <i>In Vitro</i> Test Method Accuracy .....	4-6
4.3	Availability of Original Records for the <i>In Vivo</i> Reference Data .....	4-6
4.4	<i>In Vivo</i> Data Quality .....	4-6
4.5	Availability and Use of Toxicity Information from the Species of Interest.....	4-7
4.6	Information on the Accuracy and Reliability of the <i>In Vivo</i> Test Method.....	4-7
<b>5.0</b>	<b>Test Method Data and Results.....</b>	<b>5-1</b>
5.1	Test Method Protocol.....	5-1
5.2	Availability of Copies of Original Data Used to Evaluate Test Method Performance.....	5-1
5.3	Description of the Statistical Approaches Used to Evaluate the Resulting Data .....	5-1
5.4	Summary of Results.....	5-2
5.5	Use of Coded Chemicals and Compliance with GLP Guidelines .....	5-3
5.6	Lot-to-Lot Consistency of Test Substances .....	5-3
5.7	Availability of Data for External Audit .....	5-3
<b>6.0</b>	<b>Relevance of the <i>In Vitro</i> Pyrogen Test Methods .....</b>	<b>6-1</b>
6.1	Accuracy of <i>In Vitro</i> Pyrogen Test Methods.....	6-1
6.1.1	Relevance of the Cryo WB/IL-1 $\beta$ Test Method.....	6-2
6.1.2	Relevance of the MM6/IL-6 Test Method.....	6-2

6.1.3	Relevance of the PBMC/IL-6 Test Method .....	6-3
6.1.3.1	Relevance of the PBMC/IL-6 Method When Using Cryo PBMCs.....	6-3
6.1.4	Relevance of the WB/IL-6 Test Method.....	6-3
6.1.5	Relevance of the WB/IL-1 $\beta$ Test Method .....	6-3
6.1.5.1	Relevance of the WB/IL-1 $\beta$ Test Method When Using 96-Well Plates.....	6-3
6.2	Summary of the Performance Statistics for <i>In Vitro</i> Pyrogen Test Methods .....	6-4
6.2.1	Discordant Results.....	6-4
6.2.2	Strengths and Limitations of <i>In Vitro</i> Pyrogen Test Methods .....	6-4
<b>7.0</b>	<b>Reliability of the <i>In Vitro</i> Pyrogen Test Methods .....</b>	<b>7-1</b>
7.1	Selection Rationale for the Substances Used to Evaluate the Reliability of <i>In Vitro</i> Pyrogen Test Methods .....	7-1
7.2	Analysis of Intralaboratory Repeatability and Reproducibility.....	7-1
7.2.1	Intralaboratory Repeatability .....	7-2
7.2.2	Intralaboratory Reproducibility.....	7-3
7.2.3	Interlaboratory Reproducibility.....	7-7
7.3	Historical Positive and Negative Control Data.....	7-8
<b>8.0</b>	<b>Test Method Data Quality.....</b>	<b>8-1</b>
8.1	Adherence to National and International GLP Guidelines.....	8-1
8.2	Data Quality Audits .....	8-1
8.3	Impact of Deviations from GLP Guidelines.....	8-1
8.4	Availability of Laboratory Notebooks or Other Records.....	8-1
8.5	Need for Data Quality .....	8-1
<b>9.0</b>	<b>Other Scientific Reports and Reviews .....</b>	<b>9-1</b>
9.1	Summaries of <i>In Vitro</i> Pyrogen Test Methods and Data from Published and Unpublished Studies .....	9-1
9.1.1	Andrade et al. (2003).....	9-1
9.1.2	Bleeker et al. (1994) .....	9-4
9.1.3	Carlin and Viitanen (2003) .....	9-4
9.1.4	Carlin and Viitanen (2005) .....	9-7
9.1.5	Daneshian et al. (2006) .....	9-7
9.1.6	Eperon et al. (1996, 1997).....	9-8
9.1.7	Marth and Kleinhappl (2002).....	9-10
9.1.8	Martis et al. (2005) .....	9-11
9.1.9	Pool et al. (1998) .....	9-11
9.1.10	Taktak et al. (1991).....	9-13
9.2	Conclusions from Scientific Literature Based on Independent Peer-Reviewed Reports and/or Reviews .....	9-13
9.2.1	De Groote et al. (1992) .....	9-14
9.2.2	Fennrich et al. (1999).....	9-14
9.2.3	Hansen and Christensen (1990).....	9-15
9.2.4	Hartung and Wendel (1996).....	9-15
9.2.5	Moesby et al. (1999).....	9-15

9.2.6 Nakagawa et al. (2002).....	9-16
9.2.7 Pool et al. (1999).....	9-16
9.2.8 Poole et al. (2003) .....	9-16
9.2.9 Schindler et al. (2004) .....	9-17
<b>10.0 Animal Welfare Considerations (Refinement, Reduction, and Replacement).....</b>	<b>10-1</b>
10.1 How the Five <i>In Vitro</i> Test Methods Will Refine, Reduce, or Replace Animal Use .....	10-1
10.2 Requirement for the Use of Animals .....	10-2
10.2.1 Rationale for the Use of Animals.....	10-2
<b>11.0 Practical Considerations .....</b>	<b>11-1</b>
11.1 Transferability of the <i>In Vitro</i> Pyrogen Test Methods.....	11-1
11.1.1 Facilities and Major Fixed Equipment.....	11-1
11.1.2 General Availability of Other Necessary Equipment and Supplies.....	11-1
11.2 Personnel Training Considerations.....	11-1
11.2.1 Required Training and Expertise Needed to Conduct the <i>In Vitro</i> Pyrogen Test Methods .....	11-2
11.3 Cost Considerations .....	11-2
11.4 Time Considerations .....	11-2
<b>12.0 References.....</b>	<b>12-1</b>
<b>13.0 Glossary .....</b>	<b>13-1</b>
<b>Appendix A ECVAM BRDs and Standard Operating Procedures .....</b>	<b>A-1</b>
A1 The Human Whole Blood (WB)/Interleukin (IL)-1 $\beta$ <i>In Vitro</i> Pyrogen Test.....	A-3
A2 The Human WB/IL-1 $\beta$ <i>In Vitro</i> Pyrogen Test: Application of Cryopreserved (Cryo) Human WB .....	A-133
A3 The Human WB/IL-6 <i>In Vitro</i> Pyrogen Test.....	A-237
A4 The Human Peripheral Blood Mononuclear Cell (PBMC)/IL-6 <i>In Vitro</i> Pyrogen Test.....	A-335
A5 The Monocytoid Cell Line Mono Mac 6 (MM6)/IL-6 <i>In Vitro</i> Pyrogen Test.....	A-459
<b>Appendix B ECVAM Response to ICCVAM Questions.....</b>	<b>B-1</b>
<b>Appendix C Additional Information Requested by the Panel .....</b>	<b>C-1</b>
C1 ESAC Statement on the Validity of <i>In Vitro</i> Pyrogen Tests .....	C-3
C2 Press Release: "Fewer Tests on Animals and Safer Drugs: New EU Tests Save 200,000 Rabbits per Year" .....	C-9
C3 ECVAM Replies to Questions of ICCVAM Pyrogenicity Peer Review Panel .....	C-15
C4 Rationale for the Selection of the 10 Substances Tested in the Validation/Catch-Up Validation Study of <i>In Vitro</i> Assays for Pyrogen Testing .....	C-21
C5 Comparison and Validation of Novel Pyrogen Tests Based on the	

	Human Fever Reaction: Trial Data Report.....	C-25
C6	List of Drugs for the Catch-Up Validation Study.....	C-41
C7	Analytical Procedure to Identify and Eliminate Outlying Observations .....	C-45